News from ardelyx A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 07, 2019, 16:02 ET Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights

Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for ...


Mar 14, 2019, 17:00 ET Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors

Ardelyx, Inc. (NASDAQ: ARDX), today announced the appointment of Geoffrey A. Block, M.D., Vice President, Nephrology at Reata and former Director of...


Mar 07, 2019, 17:00 ET Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology

Ardelyx, Inc. (Nasdaq: ARDX) today announced the publication in the Journal of the American Society of Nephrology (JASN) of results from the first of ...


Mar 06, 2019, 16:05 ET Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with ...


Feb 21, 2019, 08:00 ET Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at ...


Feb 07, 2019, 06:30 ET Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan

Ardelyx, Inc. (NASDAQ: ARDX) (Ardelyx) today announced that its collaboration partner in Japan, Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151) (Kyowa...


Nov 13, 2018, 08:30 ET Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C

Ardelyx, Inc. (Nasdaq: ARDX), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) ...


Nov 07, 2018, 16:05 ET Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights

Ardelyx, Inc. (Nasdaq: ARDX), today reported business highlights and financial results for the third quarter ended September 30, 2018. "During our...


Oct 26, 2018, 13:01 ET Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus

Ardelyx, Inc. (Nasdaq: ARDX), today announced the presentation of preclinical data suggesting therapeutic synergy of tenapanor in combination with...


Oct 08, 2018, 08:01 ET Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting

Ardelyx, Inc. (Nasdaq: ARDX), today announced that new data from its long-term safety trial of tenapanor for irritable bowel syndrome with...


Oct 04, 2018, 06:30 ET Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders

Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an investor event called "Renal Day" on Thursday, Oct. 11, 2018, from 8 to 10 a.m. ET ...


Sep 13, 2018, 06:30 ET Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration

Ardelyx, Inc. (Nasdaq: ARDX), today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)...


Aug 29, 2018, 14:16 ET Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption

Ardelyx, Inc. (Nasdaq: ARDX), today announced that the novel mechanism of action for tenapanor for the treatment of hyperphosphatemia, or elevated...


Aug 07, 2018, 16:01 ET Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights

Ardelyx, Inc. (NASDAQ: ARDX), today reported business highlights and financial results for the second quarter ended June 30, 2018. "Our focus during...


Aug 01, 2018, 06:30 ET Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call

Ardelyx, Inc. (NASDAQ: ARDX) today announced that it plans to report its second quarter 2018 financial results after market close on Tuesday, August...


May 29, 2018, 06:30 ET Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the ...


May 22, 2018, 06:01 ET Ardelyx Announces Pricing of Public Offering of Common Stock

Ardelyx, Inc. (Nasdaq: ARDX) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public...


May 21, 2018, 04:02 ET Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank

Ardelyx, Inc. (Nasdaq: ARDX), today announced it has entered into a $50.0 million senior secured term loan facility with Solar Capital Ltd. and the...


May 21, 2018, 04:01 ET Ardelyx Announces Proposed Public Offering of Common Stock

Ardelyx, Inc. (Nasdaq: ARDX), today announced that it has commenced an underwritten public offering of up to $50,000,000 of shares of its common...


May 08, 2018, 04:05 ET Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights

Ardelyx, Inc. (NASDAQ: ARDX), today reported business highlights and financial results for the first quarter ended March 31, 2018. "The first quarter ...


Feb 12, 2018, 06:30 ET Ardelyx Announces Departure of Chief Scientific Officer

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Jeremy Caldwell, Ph.D., chief scientific officer, will be leaving the company, effective February...


Feb 08, 2018, 06:30 ET Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at ...


Jan 03, 2018, 06:35 ET Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the ...


Jan 03, 2018, 06:30 ET Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C

Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company successfully completed the safety extension portion of its Phase 3 T3MPO program,...


Dec 11, 2017, 05:00 ET Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China

Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial...